Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in advanced temporal bone squamous cell carcinoma
NCT05444673Phase 4Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of pembrolizumab in Temporal bone squamous cell carcinoma (TBSCC), sponsored by Sun Yat-sen Memorial Hospital. Status: unknown.
02
Drugs
03
Conditions
Temporal bone squamous cell carcinoma (TBSCC)
Beyond the preview
Go deeper on NCT05444673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05444673.